(Q36675465)

15 August 2017

1 reference

title

The role of basiliximab induction therapy in organ transplantation (English)

1 reference

15 August 2017

main subject

organ transplantation

1 reference

Carlo B Ramirez

1

1 reference

15 August 2017

Ignazio R Marino

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

137-148

1 reference

Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Role of anti-interleukin-2 receptor antibodies in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Basiliximab induction improves the outcome of renal transplants in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Immunosuppression: evolution in practice and trends, 1993-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Steroid-free liver transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Comparative study of basiliximab treatment in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Basiliximab in lung transplantation: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

The role of newer monoclonal antibodies in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

The renal-sparing efficacy of basiliximab in adult living donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Can antibody prophylaxis allow sparing of other immunosuppressives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Economic analysis of basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.137

21 January 2018

Identifiers

DOI

10.1517/14712598.7.1.137

1 reference

15 August 2017

1 reference